Author(s): .

Journal Name: Current Pharmaceutical Biotechnology

Volume 17 , Issue 9 , 2016


Corrigendum to Manuscript “Pfeifer T, Buchebner M, Chandak PG, Patankar J, Kratzer A, Obrowsky S, Rechberger GN, Kadam RS, Kompella UB, Kostner GM, Kratky D, Levak-Frank S. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol. 2011 Feb 1;12(2):285-92.” LC-MS internal standard peak areas used in the calculation of brain DMHCA levels in the original manuscript were in error. Brain tissue levels were recalculated using valid internal standard peak areas and the revised Figure 6C is presented below. Thus, brain DMHCA concentration was low and variable at 1.74 +/- 1.15 µg/g tissue but not undetectable, with the concentrations being lower relative to several other tissues.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [846 - 846]
Pages: 1
DOI: 10.2174/138920101709160606123055

Article Metrics

PDF: 21